Enanta Pharmaceuticals (ENTA) Earnings Date & Reports

Key Takeaways

• Upcoming Report: Enanta Pharmaceuticals is scheduled to release its fiscal third-quarter 2026 results (quarter ended June 30, 2026) on Monday, August 10, 2026, after market close.
• Consensus Estimates: Wall Street analysts expect a net loss of approximately $0.46 to $0.51 per share, with revenue estimates clustered around $17.9 million, primarily from AbbVie royalty streams.
• Beat Streak: Enanta has exceeded consensus EPS estimates in seven of its last eight quarterly reports, most recently delivering a $0.45 per-share loss in Q2 FY2026 against a $0.46 consensus expectation.
• Pipeline in Focus: Investor attention will center on clinical updates for zelicapavir (RSV), EDP-978 (KIT inhibitor), EPS-3903 (STAT6 inhibitor), and the newly announced MRGPRX2 immunology program.
• Cash Runway: The company ended its last reported quarter with $241.9 million in cash, equivalents, and marketable securities, with management projecting sufficient funding into fiscal 2029.
• Stock Under Pressure: ENTA shares closed at $12.73 on July 27, 2026, down roughly 19% year-to-date and approximately 26% below the 52-week high of $17.15 reached in late December 2025.

Earnings Context and Why It Matters

Enanta Pharmaceuticals (NASDAQ: ENTA) is a clinical-stage biotechnology company that derives nearly all of its current revenue from royalty payments tied to AbbVie's hepatitis C virus (HCV) treatment MAVYRET/MAVIRET. While those royalties provide a steady funding stream, the investment case increasingly hinges on the company's pipeline of wholly owned drug candidates targeting respiratory syncytial virus (RSV) and immunological diseases driven by type 2 inflammation. This earnings report arrives at a pivotal moment: the company is conducting Phase 3-enabling activities for zelicapavir, its lead RSV candidate, while advancing three immunology programs toward critical milestones. For investors, the quarterly update offers a window into both the stability of the royalty income that funds operations and the clinical progress that shapes Enanta's long-term value proposition.

Earnings Expectations

For the fiscal third quarter ended June 30, 2026, analyst consensus points to a net loss in the range of $0.45 to $0.51 per share, with revenue estimates clustering near $17.9 million. This compares to a loss of $0.85 per share on revenue of $18.3 million in the same quarter a year ago (Q3 FY2025), reflecting the significant year-over-year reduction in operating expenses that has narrowed quarterly losses.

In the most recently reported quarter (Q2 FY2026, ended March 31, 2026), Enanta posted revenue of $17.2 million and a loss of $0.45 per share, topping consensus EPS estimates by $0.01. The company has now surpassed Wall Street expectations in seven of the last eight quarters, driven by disciplined cost management. Research and development (R&D) expenses fell to $20.9 million in Q1 FY2026 from $27.7 million a year earlier, while general and administrative (G&A) costs dropped to $9.0 million from $12.8 million, reflecting reduced clinical trial spending on RSV programs and lower legal expenses following the conclusion of patent litigation against Pfizer.

Key metrics investors will watch beyond headline numbers include: royalty revenue trends from AbbVie's MAVYRET franchise, R&D expense trajectory as immunology programs advance toward IND (Investigational New Drug) filings, updates on the zelicapavir Phase 3 preparation and regulatory discussions with the FDA (U.S. Food and Drug Administration), and the overall cash position against the projected runway into fiscal 2029.

AI Screener

For investors seeking to track earnings season opportunities across the biotechnology sector and beyond, Tickeron's AI Screener offers a powerful way to filter the market using AI-driven technical and fundamental signals. The platform scans thousands of stocks and ETFs (exchange-traded funds), allowing users to customize their search by industry, market capitalization, technical indicators, volatility patterns, and price movement criteria. Whether identifying breakout candidates, tracking earnings momentum, or uncovering under-the-radar biotech names with favorable setups, the AI Screener replaces hours of manual research with efficient, data-driven discovery. Explore the tool to see how AI-powered screening can sharpen your market monitoring ahead of key events like the upcoming Enanta Pharmaceuticals earnings release.

Market Reaction and Investor Sentiment

ENTA shares have faced downward pressure heading into this earnings report, declining approximately 19% year-to-date and trading near the lower end of their 52-week range of $6.45 to $17.15. The stock closed at $12.73 on July 27, 2026, reflecting a market capitalization of roughly $370 million. Sentiment appears cautious: while the consensus analyst rating remains a "Strong Buy" with an average price target of approximately $21.17 (implying over 66% upside), the stock's recent trajectory suggests investors are awaiting clearer clinical catalysts before re-engaging.

Historically, ENTA has experienced mixed post-earnings price movement. Following the Q2 FY2026 report in May, which featured a modest EPS beat, the stock drifted lower in subsequent weeks. Key sentiment drivers for the upcoming report include any updated guidance on clinical timelines, signals around partnership discussions for RSV assets, and management's commentary on the pace of immunology pipeline advancement. The biotechnology sector's broader risk appetite—particularly for pre-revenue, clinical-stage companies—also remains a factor as interest rate expectations continue to influence capital flows into the space.

Forward Outlook and Key Factors to Monitor

Looking beyond the August 10 report, several catalysts will shape Enanta's trajectory through the remainder of fiscal 2026 and into 2027.

The most closely watched development is the progress of zelicapavir toward a Phase 3 clinical trial. Following positive topline data from the RSVHR Phase 2b study in high-risk adults, announced in September 2025, the company has been conducting Phase 3-enabling activities including discussions with the FDA. Any update on the design, timing, or partnership strategy for the pivotal trial could serve as a significant stock-moving event. Investors are also watching for developments around EDP-323, Enanta's second RSV candidate targeting the L-protein, which could be used in combination with zelicapavir.

In immunology, three programs are advancing in parallel. The company planned to file an IND for EDP-978, its oral KIT inhibitor, in the first quarter of calendar 2026, with Phase 1 data expected in the fourth quarter of 2026. A second IND filing for EPS-3903, the STAT6 inhibitor development candidate targeting type 2 immune-driven diseases including atopic dermatitis and asthma, is expected in the second half of 2026. Additionally, the newly introduced MRGPRX2 inhibitor program is on track to select a development candidate in the second half of 2026.

On the financial side, Enanta's cash position remains a source of stability. With $241.9 million as of the last reported quarter, supplemented by retained royalty revenue from AbbVie (after the 54.5% share paid to OMERS under the royalty sale agreement), management has guided that operations are funded into fiscal 2029. However, investors will monitor whether rising R&D costs from the expanding immunology pipeline begin to pressure this runway, and whether any partnership or licensing deals for the RSV franchise could provide non-dilutive capital.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations